ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Authors
Keywords
Kinase inhibitors, Gene expression, Transport inhibition assay, Patients, Hyperexpression techniques, Polymerase chain reaction, Protein interactions, Tyrosine kinase inhibitors
Journal
PLoS One
Volume 13, Issue 1, Pages e0192180
Publisher
Public Library of Science (PLoS)
Online
2018-02-01
DOI
10.1371/journal.pone.0192180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
- (2016) L N Eadie et al. LEUKEMIA
- ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
- (2016) Laura N. Eadie et al. PLoS One
- The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia
- (2014) A Giannoudis et al. LEUKEMIA
- Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance
- (2013) Timo Hupfeld et al. BRITISH JOURNAL OF HAEMATOLOGY
- Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
- (2013) L N Eadie et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The ABCC6 transporter: what lessons can be learnt from other ATP-binding cassette transporters?
- (2013) Olivier M. Vanakker et al. Frontiers in Genetics
- Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
- (2012) Ophelia Q. P. Yin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells
- (2012) D L White et al. LEUKEMIA
- Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
- (2012) Laura N. Eadie et al. LEUKEMIA & LYMPHOMA
- Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells?
- (2012) Petr Kosztyu et al. PHARMACOLOGICAL RESEARCH
- Mammalian multidrug-resistance proteins (MRPs)
- (2011) Andrew J. Slot et al. Essays in Biochemistry
- Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases
- (2011) Zhe-Sheng Chen et al. FEBS Journal
- Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways
- (2011) Carine Tang et al. LEUKEMIA & LYMPHOMA
- Multidrug resistance associated proteins in multidrug resistance
- (2011) Kamlesh Sodani et al. Chinese Journal of Cancer
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
- (2008) Shu-Feng Zhou et al. CURRENT MEDICINAL CHEMISTRY
- The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
- (2008) Gergely Szakács et al. DRUG DISCOVERY TODAY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now